Who Owns Integrated DNA Technologies?

• Parent Company: Danaher Corporation
• Ownership Type: Wholly owned
• Acquisition Year: 2018
• Company Type: Publicly Traded
• Stock Ticker: NYSE: DHR

• Founded: 1987
• Founders: Integrated DNA Technologies founding team
• Acquired by Danaher Corporation: 2018

• Founded: 1969
• Headquarters: Washington, D.C., USA
• Company Type: Publicly Traded
• Stock: NYSE: DHR
• Revenue: $24.6 billion (FY2025)
• Employees: Approximately 63,000

Visit Danaher Corporation website

• Headquarters: Coralville, Iowa, USA
• Manufacturing / Operations: United States, Europe

Integrated DNA Technologies (IDT) operates under Danaher's comprehensive sustainability framework, implementing environmental responsibility programs, ethical business practices, and sustainable manufacturing processes in the genomics industry. As a leader in oligonucleotide synthesis and genomics solutions, IDT demonstrates commitment to sustainability while maintaining its position as an innovative genomics company.

Environmental Sustainability and Green Manufacturing: IDT has implemented comprehensive sustainability initiatives across its operations, focusing on waste reduction, energy efficiency, and sustainable manufacturing practices. The company's Leuven site in Belgium has achieved zero waste-to-landfill status, demonstrating IDT's commitment to eliminating waste from its manufacturing processes. IDT has reduced organic solvent usage through participation in the US EPA Beneficial Reuse Program, minimizing environmental impact while maintaining production efficiency. The company's Innovation Headquarters in Coralville, Iowa, spanning 150,000 square feet, leads IDT's sustainability efforts and serves as a model for environmentally conscious facility design.

Energy Efficiency and Renewable Energy: IDT has invested significantly in energy efficiency improvements across its facilities. The company has implemented LED lighting systems that result in 90% energy efficiency gains compared to traditional lighting solutions. IDT utilizes geothermal heating and cooling systems at its facilities, reducing reliance on traditional energy sources and minimizing carbon footprint. These energy efficiency initiatives contribute to IDT's long-term sustainability goals, including achieving net-zero value chain greenhouse gas emissions by 2050 and reducing scope 1 and scope 2 greenhouse gas emissions by 50.4% by 2032.

Sustainable Packaging and Shipping: IDT has implemented sustainable packaging solutions throughout its shipping and distribution operations. All shipping envelopes used by IDT are fully biodegradable, reducing plastic waste and environmental impact. The company's shipping containers are made with more than 85% recycled materials, demonstrating IDT's commitment to circular economy principles and sustainable supply chain practices. These packaging initiatives help minimize the environmental footprint of IDT's global distribution network while ensuring product safety and quality.

Waste Reduction and Recycling Programs: IDT maintains comprehensive waste reduction and recycling programs across its operations. The company recycles all hard plastics and gloves used in manufacturing and research operations, diverting significant waste from landfills. IDT's waste reduction efforts include both operational waste and packaging materials, with the company continuously seeking opportunities to minimize waste generation and improve recycling rates. These programs reflect IDT's broader commitment to environmental stewardship and responsible manufacturing practices.

Supply Chain Ethics and Responsibility: As part of Danaher Corporation, IDT adheres to Danaher's Sustainability Policy, Sustainable Supply Chain Policy, and Global Environmental, Health and Safety Policy. The company maintains comprehensive supply chain responsibility programs that ensure ethical sourcing, fair labor practices, and environmental compliance across its supplier network. IDT requires suppliers to meet strict environmental and social responsibility standards, extending the company's sustainability commitment throughout its value chain.

Research Ethics and Biosecurity: IDT maintains strong ethical standards in genomics research and development, including comprehensive biosecurity protocols and responsible research practices. The company provides biosecurity attestations and follows strict guidelines for the ethical use of genetic materials and technologies. IDT's research ethics programs ensure compliance with international regulations and best practices in genomics research, protecting both scientific integrity and public safety.

Transparency and Corporate Responsibility: IDT operates with transparency in its sustainability initiatives and corporate responsibility practices. The company regularly reports on its environmental performance, sustainability goals, and progress toward targets. IDT's sustainability efforts have been recognized with awards including the Kimberly-Clark Greenovation award for 7 of the past 8 years, acknowledging the company's leadership in sustainable manufacturing and environmental innovation.

Integrated DNA Technologies has received significant recognition for its innovation in genomics solutions, contributions to biotechnology research, and leadership in the oligonucleotide manufacturing industry. The brand's awards and accolades reflect its role in advancing molecular biology research and supporting scientific discovery worldwide.

IDT Sustainability Award Program: Integrated DNA Technologies established the IDT Sustainability Award to support innovation in biodiversity research, demonstrating the company's commitment to environmental sustainability and scientific advancement. The award program recognizes researchers and institutions working on biodiversity conservation and environmental genomics projects, highlighting IDT's role in supporting sustainable scientific research and environmental stewardship.

Genomics Innovation Leadership: IDT has been acknowledged for its three decades of contribution to powering the genomics revolution, enabling scientists to decode biology with growing precision and speed. The company's NGS innovation roadmap and continued investment in next-generation sequencing technologies have been recognized as advancing the future of cancer research and molecular diagnostics.

Industry Technology Recognition: IDT's custom oligonucleotide synthesis technology and manufacturing capabilities have been acknowledged as industry-leading, with the company growing from a startup with 10 synthesizing machines to a major manufacturer shipping an average of 75,000 custom oligos per day to more than 82,000 customers worldwide. This growth trajectory and technical innovation have been recognized as significant achievements in the biotechnology manufacturing sector.

Research Community Recognition: IDT has received recognition from the scientific research community for its reliability, quality, and innovation in nucleic acid products. The company's products are used in diagnostic tests for many forms of cancer and most inherited and infectious diseases, contributing to critical healthcare advancements and scientific discoveries.

Agricultural Biotechnology Impact: IDT's oligonucleotides have been acknowledged for their instrumental role in decoding genomic DNA from millions of crop varieties worldwide, helping develop crops that withstand droughts, diseases, and pest outbreaks. This contribution to agricultural biotechnology and food security has been recognized as supporting global sustainability efforts.

Danaher Integration Success: Following its acquisition by Danaher Corporation in 2018, IDT has been recognized for successful integration into Danaher's Life Sciences segment while maintaining its innovation culture and customer focus. The $1.9 billion acquisition highlighted IDT's strategic value and market position in the genomics solutions market.

Manufacturing Excellence Recognition: IDT's manufacturing facilities and quality control systems have been acknowledged for excellence in producing high-quality nucleic acid products for academic research, biotechnology, agriculture, medical diagnostics, and pharmaceutical development applications. The company's commitment to quality and consistency has been recognized as a key differentiator in the competitive biotechnology market.

Scientific Community Partnerships: IDT has been recognized for its partnerships with research institutions, universities, and biotechnology companies, supporting collaborative research initiatives and advancing scientific knowledge in genomics and molecular biology.

Strategic Partnership and Collaboration Recognition: IDT's strategic partnerships and collaborations have been recognized for advancing scientific research and therapeutic development. The company's partnership with the Innovative Genomics Institute (IGI) through the Danaher-IGI Beacon for CRISPR Cures has been acknowledged as a significant initiative to harness CRISPR-based gene editing power and accelerate therapeutic development. IDT's collaboration with Molecular Health to integrate NGS capabilities has also been recognized for streamlining genomic workflows and accelerating cancer research.

Technology Innovation Recognition: IDT has been acknowledged for technological innovations including its new custom vector onboarding tool that allows researchers to skip in-house cloning and receive 100% sequence-verified clonal DNA. This innovation has been recognized for saving researchers time and improving efficiency in gene synthesis workflows. The company's continuous development of new tools and technologies for genomics research has been acknowledged as contributing to scientific advancement and research productivity.

Global Expansion and Market Leadership Recognition: IDT's growth from a small startup to a global genomics leader has been recognized as a remarkable success story in the life sciences industry. The company's expansion across multiple continents and its ability to serve a global customer base of more than 82,000 customers demonstrates exceptional market development and customer service capabilities. IDT's achievement of becoming a trusted partner for researchers and diagnostics companies globally has been acknowledged as a significant accomplishment in the competitive genomics market.

Environmental Leadership Recognition: Beyond the Kimberly-Clark Greenovation awards, IDT has been recognized for its environmental leadership in achieving zero waste-to-landfill status at its Leuven site and implementing comprehensive sustainability programs. The company's commitment to net-zero greenhouse gas emissions by 2050 and its 50.4% reduction target for scope 1 and scope 2 emissions by 2032 have been acknowledged as ambitious and meaningful climate action goals.

Community and Industry Engagement Recognition: IDT's active engagement with the scientific community through sponsorships, educational initiatives, and industry partnerships has been recognized as contributing to the advancement of genomics research and education. The company's support of iGEM competitions and other scientific education programs demonstrates its commitment to fostering the next generation of scientists and advancing genomics education.

Integrated DNA Technologies has maintained a strong operational record throughout its history, though the brand has faced some challenges related to workforce restructuring, intellectual property disputes, and the competitive dynamics of the genomics industry. These issues have tested the company's ability to navigate market changes while maintaining its position as a leader in genomics solutions.

Workforce Restructuring (December 2025): IDT conducted layoffs across its Iowa operations in December 2025, affecting 4.7% of the company's Iowa workforce. The company confirmed the restructuring as part of a strategic effort to "refocus resources to sustain future growth and support our long-term business objectives." IDT stated that these "measured changes reflect IDT's ongoing transformation as a global leader in genomics and positions our business capabilities to evolve with changing customer demands." The company provided affected workers with severance and support packages, though the specific timing and number of affected employees were not disclosed. This restructuring reflects the broader challenges facing life sciences companies in adapting to changing market conditions and customer demands.

Intellectual Property and Patent Disputes: IDT has been involved in intellectual property disputes, particularly in the competitive oligonucleotide synthesis market. In December 2024, the company was involved in a patent dispute case before the United States Court of Appeals for the Federal Circuit, where IDT argued about the interpretation of patent claims related to primer annealing and secondary structure formation in nucleic acid amplification. Such intellectual property disputes are common in the genomics industry, where companies seek to protect their technological innovations and market positions through patent protection.

Market Competition and Pricing Pressures: IDT operates in the highly competitive genomics and oligonucleotide synthesis market, facing competition from both established players and emerging companies. The company has faced ongoing pressure to maintain competitive pricing while investing in research and development and manufacturing capabilities. This competitive environment creates challenges for maintaining profitability while continuing to invest in innovation and customer service.

Regulatory Compliance Challenges: As a provider of genomics products and services, IDT must navigate complex regulatory requirements related to research use products, diagnostic applications, and emerging technologies like CRISPR gene editing. The company must ensure compliance with various regulatory frameworks across different markets and applications, creating ongoing compliance challenges and requiring significant resources for regulatory affairs and quality management.

Technology Transition and Innovation Pressure: The rapid pace of technological advancement in genomics creates pressure on IDT to continuously innovate and update its product offerings. The company must invest in research and development to maintain its competitive position in areas such as next-generation sequencing, CRISPR gene editing, and synthetic biology. Failure to keep pace with technological change could threaten IDT's market position and customer relationships.

Supply Chain and Manufacturing Complexity: IDT's global operations and complex manufacturing processes create ongoing challenges related to supply chain management, quality control, and operational efficiency. The company must maintain high-quality standards across its manufacturing facilities while managing costs and ensuring reliable supply to customers worldwide. Supply chain disruptions or quality issues could impact customer relationships and market reputation.

Integration Challenges Following Danaher Acquisition: Since its acquisition by Danaher Corporation in 2018, IDT has faced integration challenges related to aligning its operations with Danaher's business systems and corporate culture while maintaining its scientific innovation and customer focus. The integration process has required balancing operational efficiency with the preservation of IDT's entrepreneurial culture and scientific expertise.

Research Funding and Market Cycles: IDT's business is partially dependent on research funding patterns and market cycles in the life sciences industry. Changes in research funding, economic conditions, or research priorities can impact demand for IDT's products and services, creating revenue volatility and requiring flexible business strategies.

Ethical Considerations in Genomics Research: As a provider of genomics tools and technologies, IDT faces ongoing ethical considerations related to the use of its products in various applications, including genetic research, diagnostics, and therapeutic development. The company must navigate complex ethical questions related to genetic privacy, research ethics, and the responsible use of genomics technologies.

Global Expansion and Cultural Challenges: IDT's global operations create challenges related to cultural differences, regulatory variations, and market dynamics across different regions. The company must adapt its products, services, and business practices to local market conditions while maintaining consistent quality standards and corporate values across its global operations.